1. 擔任國際臨床試驗總主持人: (針對健康的嬰幼童，評估含佐劑之不活化腸病毒71型 (EV71) 疫苗的效力、免疫生成性與安全性之多中心、雙盲、隨機分配、安慰劑對照的第三期試驗; NCT05099029)，用以評估疫苗的臨床效力、免疫生成性、安全性、交叉保護力等。此項臨床數據，已發表於國際醫學期刊「Lancet」。 2. 對於兒童感染症的研究極具貢獻。 3. 參與各項兒童疫苗上市前臨床試驗及小分子抗病毒藥物早期臨床試驗。

1. The diet therapy of inflammatory bowel disease: a multi-omic analysis(發炎性腸症之飲食治療：多體學的分析) − Inflammatory Bowel Disease (IBD) − Crohn's Disease − Nutrition therapy microbiota − Crohn's disease exclusion diet 2. Study to Evaluate Efficacy and Safety of MS-20 on Patients with Ulcerative Colitis(MS-20於潰瘍性腸炎病人之效用及安全性) − Ulcerative colitis − MS-20 3. Minimize the Risk of Infection-Related Cancers by Implementation of Microbiota Reprogramming(實施微生物相重新編程以極少化感染性癌症之風險) − HBV − HIV − HPV − nasopharngeal carcinoma − microbiology 4. Development of novel anti-allergic probiotics by gut microbiota metagenomic analysis in infant cohorts(以新生兒世代腸道菌叢分析開發新型抗過敏益生菌) − Allergic diseases − Gut microbiota − metabolites − Prebiotics − Probiotics 5. A Phase 3 Randomized, Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Golimumab Treatment, a Human anti-TNFα Monoclonal Antibody, Administered Subcutaneously in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis (一項第3期隨機分配的開放性試驗，針對患有中度至重度活性潰瘍性大腸炎的小兒患者，評估皮下注射人類抗TNFα單株抗體Golimumab的療效、安全性和藥物動力學，PURSUIT 2) − Ulcerative colitis − Pediatric 6. Explore the biomarkers determining the evolution of liver fibrosis and the outcome of pediatric chronic liver disease(探討影響肝纖維化演進與兒童慢性肝病預後的生物標誌物) − Microbiota 7. Gut microbiota play a critical role in determining the age-dependent outcome of hepatitis B virus infection(腸道菌群在決定B型肝炎病毒感染年齡依賴性的結果扮演重要的角色) − Microbiota 8. The oncofetal RBMY protein and gut microbiota dysbiosis facilitate the development and metastasis of hepatocellular carcinoma(癌胚蛋白質RBMY與腸道菌生態失調促成肝癌發展並轉移) − Hepatocellular Carcinoma (HCC) − Metastasis − microbiota − Epithelial–Mesenchymal Transition 9. Explore the clinical impacts of cell-free DNA as a noninvasive diagnosis of liver injury in pediatric liver transplant patients(在兒童肝臟移植患者研究無細胞去氧核醣核酸作為急性肝臟損傷的非侵入性診斷工具) − Liver transplant 10. Development of precision microbiome-based interventions in chronic hepatitis B (運用微生物體之精準醫學控制慢性B型肝炎) − Chronic hepatitis B − Gut microbiota 11. Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-ADOLESCENTS-2) Tirzepatide每週一次用於治療青少年肥胖和體重相關共病相較於安慰劑的療效和安全性：一項隨機分配、雙盲、安慰劑對照試驗 (SURMOUNT-ADOLESCENTS-2) - Pediatric - Obesity